Opinion|Videos|November 21, 2025
Reinstating LDL-C Targets
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
Advertisement
Episodes in this series
Panelists discuss how reinstating low-density lipoprotein cholesterol (LDL-C) targets could realign quality programs toward outcomes-driven care. Setting measurable goals encourages clinicians to intensify therapy and monitor progress.
They emphasize that outcomes-based incentives could harmonize payer and provider priorities, fostering accountability across systems. Restoring LDL-C targets may also reduce variability and close treatment gaps by making success measurable.
The discussion underscores that combining statin adherence metrics with LDL-C goal attainment could produce the most balanced and impactful framework.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5